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Whereas red blood cell transfusions have been used since the 19th century, plasma has only been available since
1941. It was originally mainly used as volume replacement, mostly during World War II and the Korean War. Over
the years, its indication has shifted to correct coagulation factors deficiencies or to prevent bleeding. Currently, it
remains a frequent treatment in the intensive care unit, both for critically ill adults and children. However,
observational studies have shown that plasma transfusion fail to correct mildly abnormal coagulation tests.
Furthermore, recent epidemiological studies have shown that plasma transfusions are associated with an increased
morbidity and mortality in critically ill patients. Therefore, plasma, as any other treatment, has to be used when the
benefits outweigh the risks. Based on observational data, most experts suggest limiting its use either to massively
bleeding patients or bleeding patients who have documented abnormal coagulation tests, and refraining for
transfusing plasma to nonbleeding patients whatever their coagulation tests. In this paper, we will review current
evidence on plasma transfusions and discuss its indications.
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What is plasma?
Plasma units are biological products containing the acel-
lular portion of blood obtained from a whole-blood do-
nation after centrifugation or by plasmapheresis. Most
plasma units contain 200 to 250 ml, but plasmapheresis-
derived units may contain as much as 400 to 600 ml.
Plasma has been available for transfusion since 1941
and was initially mainly used as volume replacement [1].
Its use rapidly spread in the context of World War II
and the Korean War for the treatment of traumatic
shock [2]. With emergence of crystalloids and purified
albumin, as well as with the recognition of hepatitis
transmission and transfusion related side effects, its use
as volume expander has progressively declined.
Plasma constitution
Plasma units contain many biologically active molecules [3]:
– Proteins: 5.5 g/dl* Corr
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in any medium, provided the original work is p○ 5%: coagulation factors: 1 ml of plasma contains
approximately 1 unit of each of the coagulation
factors, with some heterogeneity [4].
○ Fibrin
○ Immunoglobulins
○ Antithrombin, Protein C and S
– Other proteins: cytokines
– Electrolytes: Glucose (535 mg/dl), sodium (172
mEq/l), potassium (15 mEq/L) [5]
– Citrate (for stabilisation).
Plasma products
Labile coagulations factors, especially factors V and VIII,
are unstable because they have a short half-life once the
unit is thawed [6]. Plasma must therefore be rapidly fro-
zen after blood donation at −18°C or below, in order to
maintain the activity of labile coagulation factors. Differ-
ent products can be manufactured:
Fresh-frozen plasma (FFP): Plasma frozen at −18°C
within 8 hours of collection, which can then be stored
for up to 1 year.
Frozen plasma (FP): Plasma frozen within 24 hours of
collection. All the clotting factors are at the same levelis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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normal) [6,7]. These levels are deemed adequate for
haemostasis.
Pooled fresh-frozen plasma: As there is a high
variability in coagulation factors between single donor
units of FFP [3], pooling plasma from many donors
(of identical ABO blood group) provides a method to
maintain a constant concentration of these factors.
However, pooling donors increases the risks of
transmission of infectious diseases. To reduce this risk,
multiple pathogen inactivation methods are used, such
as solvent/detergent (SD) treatment, methylene blue
(MB), ultraviolet light with riboflavin, and psoralens
(amotosalen). SD-FFP inactivates enveloped virus but
has no effect on hepatitis A virus and parvovirus B19.
SD-FFP also seems to reduce HLA concentrations and
bioactive lipids, which could lead to fewer immunologic
adverse effects [8].
MB-FFP has low factor VIII (FVIIII) and fibrinogen
activity, whereas SD-FFP has reduced activity of VWF
et FVIII as well as lower functional activity of protein
S. Therefore, SD-FFP should not be used in patients
with IgA or severe protein S deficiency. However,
although FFP and SD-FFP differ in several aspects [9],
they are considered to be interchangeable in most
European countries.
Thawed plasma: FFP or FP thawed at 37°C (if thawed
at 4°C, cryoprecipitate will form) and then stored for
up to 5 days at 1 to 6°C [10]. The advantage of thawed
plasma is its availability for immediate use. It therefore
can be used rapidly, for example in massively bleeding
patients. Nevertheless, it should not be used if either
factor V or factor VIII is specifically needed because of
the decline of their activity [1]. Furthermore, its
usefulness and safety has not been demonstrated yet in
neonates and infants.
Cryoprecipitate: Cryoprecipitate is prepared by thawing
frozen plasma at 1°C to 6°C, which causes some
proteins to precipitate. This cryoprecipitate is rich in
fibrinogen, factor VIII, factor XIII, and von Willebrand
factor (vWF). It is then refrozen at −18°C and can be
stored up to 1 year.
What are the clinical effects of plasma?
What is the effect of plasma transfusions on coagulation
test results?
As plasma contains coagulation factors [3], its most fre-
quent indication is to correct abnormal coagulation tests
[1]. In massively bleeding patients, large-volume, crystal-
loid administration followed by RBCs alone promotes
dilutional coagulopathy. Furthermore, active bleeding
leads to coagulation factor consumption. Development
of shock and coagulopathy early after injury is strongly
associated with mortality [11]. Plasma transfusions canconstitute a life-saving intervention by improving coagu-
lation factor deficit [12]. Indeed, plasma transfusions
have been shown to partially correct very abnormal
international normalized ratio (INR) levels [13].
In less dramatic situations, the impact of plasma trans-
fusions on coagulation tests has only been explored
since 2006, when Abdel-Wahab et al. assessed the effect
of plasma on INR in an adult critical care unit [14].
Among 121 critically ill adults who received plasma for
moderately abnormal coagulation tests (INR < 1.85),
only one (0.8%) was able to correct his INR (<1.1) after a
plasma transfusion. The amount of transfused plasma
was not associated with the INR after transfusion, what-
ever the volume. The authors concluded that, whatever
the volume, plasma transfusions did not correct moder-
ate coagulopathy. The same year, this was confirmed in
another observational study by Holland et al., who
showed that plasma transfusions did not correct INR
levels < 2.0–2.5 [13].
It should be noted that no study has evaluated the
effect of plasma transfusions on coagulation test
results in children. Therefore, observational data sug-
gest that plasma transfusions improve outcome in
massively bleeding patients but fails to do so in
nonmassively bleeding patients with mildly abnormal
coagulation tests.How does plasma affect the immune system?
As plasma contains many bioactive substances, such as
cytokines, it has been presumed that it could induce not-
able changes in the patient’s immunity status. This
transfusion-associated immunomodulation (TRIM) has
been described in all blood product transfusions. TRIM
effects may be mediated by: 1) allogeneic mononuclear
cells; 2) white-blood-cell (WBC)-derived soluble media-
tors; and/or 3) soluble HLA peptides circulating in allo-
geneic plasma [15]. Prestorage leucocyte depletion has
been shown to prevent TRIM [16]. Nevertheless, in vitro
studies have revealed that even leuco-depleted plasma
increased the levels of tumor necrosis factor (TNF) and
interleukine-10 (IL-10) after transfusion [17]. One might
hypothesize that this is due to the freezing process,
which ruptures the cell walls in the remaining WBC, as
leukoreduction leaves < 1×106 WBC/unit. Other studies
also have described the different effects of filtration of
interleukins, histamine, and TNF in filtrated blood com-
ponents [18]. However, clinically relevant concentrations
of these substances have never been determined [19].
All of these in vitro studies suggest that plasma is
biologically active and that it might induce immune
modifications in the recipient. However, the specific
clinical impact of these substances has still to be
assessed in vivo.
Table 2 Incidence of infectious disease transmission risks,
based on Heiden et al. [18] and on Stramer [21]
FFP SD-FFP RBC
HIV 1+2 1:10 million No reported
cases to date.
1:2.1 million
Hepatitis C 1:50 million No reported
cases
1:1.9 million
Hepatitis B 1:1–2 million No reported
cases
1:205 000–488 000
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Infections
As for all other transfusions, plasma also is associated
with transfusion-transmitted infectious diseases. How-
ever, plasma transfusions are associated with a much
lower risk of bacterial infections (<0.1/100,000) than
RBCs (0.4/100,000) and platelets (2.9/100,000) [20]. This
might be due to the freezing process per se, which inacti-
vates bacteria.
Apart from donor screening (Table 1), multiple patho-
gen inactivation methods have been developed to reduce
this risk, especially for pooled plasma. Furthermore,
removal of cellular components also eliminates cell-
associated bacteria, as well as most protozoa and cell-
associated virus. However, freezing does not remove free
viruses, such as hepatitis A, B, and C, human immuno-
deficiency virus (HIV) 1+2, parvovirus B19, and prions.
Table 2 shows the incidence of some viral transmission
risks for FFP and SD-FFP compared with RBC units.
Transfusion-related acute lung injury:
Transfusion-related acute lung injury (TRALI) is de-
fined as a noncardiogenic pulmonary oedema related to
any transfusion therapy. Clinical features may be indis-
tinguishable from other causes of acute lung injury (re-
spiratory distress, hypoxia, and pulmonary infiltration).
As a result, this complication is perhaps underdiagnosed
and underreported. Most TRALI symptoms occur within
1 to 2 hours after transfusion initiation, and almost all
reactions occur by 6 hours after transfusion completion.
The mechanisms implicated consist of passive transfer
of antileukocyte antibodies (anti-human leucocyte anti-
gen [HLA]) from alloimmunized donors and the accu-
mulation of bioactive mediators in a predisposing
inflammatory condition.
Many adult studies have shown that among blood
products, plasma and platelet transfusions were the most
frequently involved in TRALI [22-24]. The UK hemo-
vigilance analysed 3,239 reports of adverse reactions and
events associated with transfusions of labile blood com-
ponents in the UK, between 1996 and 2005. Twenty of
the 185 cases of TRALI happened in paediatric patients.
In 19 of these cases (95%), the implicated component
was either plasma or platelets [25].Table 1 Common safety requirements for FFP donors
Blood test
HIV 1+2 Negative
HbsAg (surface antigen of hepatitis B virus) Negative
HCV antibody (hepatitis C virus antibody) Negative
HCV genome Negative
Treponema pallidum antibody Negative
Alanine aminotransferase (ALT) NegativeImmunomodulation
As already discussed, plasma contains many bioactive
substances, such as cytokines, immunoglobulin, and co-
agulation factors. Transfusion-related immune modula-
tion might explain why standard plasma transfusions
seem to be associated with some adverse events, such as
multiple organ dysfunction syndromes and an increased
risk of contracting nosocomial infections. Adult epi-
demiological studies have shown that patients who are
transfused with plasma are indeed more prone to noso-
comial infections (adjusted odds ratio 2.99 (95% CI
2.28–3.93)) [26] and acute respiratory distress syndrome
(adjusted odds ratio 2.48 (95% CI 1.29; 4.74)) [22].
A paediatric retrospective study evaluated the associ-
ation between plasma and mortality in 380 children with
acute lung injury (ALI) [27]. The authors showed a sig-
nificant increase in mortality (8%) for each ml/kg of FFP
transfused in paediatric patients with acute lung injury,
after adjusting for severity at admission and coagulo-
pathy. We recently published a prospective epidemio-
logical study in 831 critically ill children. The adjusted
odds ratios were 3.2 (95% CI 1.6; 6.6) and 2.3 (95% CI
1.0; 5.3) for increased incidence morbidity and nosoco-
mial infection, respectively. There also was a significant
difference in the adjusted length of stay in the intensive
care unit [28]. Although these nonrandomized studies
might be biased, plasma transfusions may be associated
with worse clinical outcome, perhaps due to their
immunomodulative properties.
Allergic reactions
Real anaphylaxis with the administration of plasma is very
rare. In the UK, there were only 23 allergic and 25 ana-
phylactic reactions imputable to plasma transfusions, dur-
ing a 6-year period [1]. In France, in 2010, allergic
reactions occurred in 0.05% of all plasma transfusions [20].
Other reactions
Plasma transfusions are associated with transfusion-
associated circulatory overload (TACO). TACO occurs
when the recipient’s circulatory system is overwhelmed
by either the rate of the infusion or the volume of blood
products transfused. TACO is characterized by the acute
onset of dyspnea and typically hypertension, tachypnea,
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natriuretic peptide (BNP) above the recipient’s baseline
level can help to differentiate TACO from TRALI. The
exact prevalence of TACO is unknown: the proportion
of adults requiring plasma transfusions who develop
TACO ranges from 0.001% to 4.8% of [20,29]; there is
no specific paediatric data.
Plasma transfusions also have been associated with
citrate toxicity, which have been described after rapid
transfusion of large volume of plasma [30]. Blood com-
ponents are anticoagulated with citrate. When trans-
fused, citrate may bind with circulating ionic calcium
and magnesium. During massive transfusion, the
capacity of the liver to metabolize citrate may be
overwhelmed, and potentiated by hypothermia or
hypotension, particularly in the presence of underlying
liver disease, leading to hypocalcaemia and/or hypomag-
nesemia. Metabolic alkalosis also may develop secondary
to the accumulation of bicarbonate, the metabolic
byproduct of citrate.What is the current practice for plasma transfusions?
In 2008, according to the U.S. Department of Health
and Human Services, 4,484,000 plasma units were trans-
fused in the United States [31]. Close to 3% of all paedi-
atric admissions [32] and more than 10% of critically ill
children [28] receive a plasma transfusion during their
stay, making plasma transfusions a frequently used treat-
ment modality.
When physicians prescribe plasma transfusions, they
usually hope to correct abnormal coagulation tests by
restoring coagulation factor levels, either with a thera-
peutic (to stop bleeding) or prophylactic (before invasive
procedures or surgery) goal. It seems that the majority
of plasma is administered in the latter circumstance. In
2004, Dzik et al. described that the most common pur-
pose of plasma transfusion was to “prepare” a patient
with an elevated international normalized ratio (INR) for
invasive procedures [33]. Lauzier et al. also showed that
plasma transfusions often were administered to patients
who were not bleeding [34]. In another prospective
study, Arnold et al. showed that 60% of the plasma was
prescribed to either nonbleeding patients or patients
with normal coagulation tests [35]. In another audit,
Shariff et al. found that 34% of the use of plasma units
in their centre was inappropriate and concluded that this
was “due to limited knowledge of its use in specific situ-
ations and ignorance of risks” [36].
We recently presented the only paediatric data regard-
ing current practice. More than two thirds of paediatric
intensivists would prescribe plasma transfusions to
nonbleeding children. For these nonbleeding critically ill
children, the median INR level that would trigger aplasma transfusion was 2.0 to 2.5, according to the clin-
ical situation [37].
This heterogeneity in plasma transfusion practice pat-
terns probably indicates a need for stronger evidence on
appropriate plasma transfusion thresholds. Once ran-
domized, controlled trials will have provided the clini-
cians with the best transfusion strategies, these will have
to be implemented. It has been shown that systemic
organizational interventions, such as educational cam-
paigns or prospective audits of plasma requests, lead to
a significant reduction in the inappropriate rate of
plasma transfusions [38].
How and when to transfuse plasma in the PICU?
The following recommendations are based on inter-
national guidelines [1,30,39,40].
Appropriate trigger
Because it has been shown that plasma transfusions fails
to correct INR < 1.85 or 2.0 [13,14], most recommenda-
tions advise to transfuse if PT ratio or aPTT ratio >1.5
[1,30] or if INR >2 [40]. Thromboelastography, a re-
cently incorporated method into ICU clinical practice, is
performed with whole blood. It assesses the viscoelastic
property of clot formation under low shear condition
[41]. Thromboelastography-based algorithms reduce
both transfusion requirements and blood loss in mas-
sively bleeding patients [42]. There is conflicting data re-
garding the predictive value of thromboelastography
tests in patients with liver disease [43,44]. However,
there is currently no data on its adequacy to evaluate the
risk of bleeding in other situations, especially in a PICU
setting. Therefore, it has not yet been incorporated in
plasma transfusion guidelines.
Physicians also must recognise that coagulation tests
are not well correlated to the risk of bleeding. In a re-
cent meta-analysis of 25 studies, Segal et al. have shown
that the risk of bleeding during different procedures
(angiography, liver biopsy, thoracocentesis, bronchos-
copy, liver laparoscopy, etc.) was similar for patients
with normal and abnormal coagulation [45].
Appropriate dose
Hemostasis can be achieved when activity of coagulation
factors is at least 25-30% of normal, because there is a
nonlinear, exponential relationship between clotting fac-
tor levels and coagulation test results [46]. In adults, be-
cause the total blood volume is approximately 65 ml/kg
and the hematocrit is approximately 0.4, the plasma
volume (i.e., the volume without RBC) is approximately
(1–0.4) × 65 ml/kg = 40 ml/kg. Therefore, to provide
30% of coagulation factor, the therapeutic transfusion
dose theoretically should be 30% × 40 ml/kg = 12 ml/kg.
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ever, no clinical trial has evaluated this dose.
Prescription of plasma transfusion
Compatibility testing is not required before plasma
transfusion, unless large volumes are given. Plasma must
be ABO compatible with the recipient’s RBCs. Type AB
plasma can be administered in severe and acute situa-
tions as a universal donor type if necessary. Rh compati-
bility and cross-matching are not considered because
there are virtually no RBCs in FFP.
Normally, it takes 20 to 30 minutes to thaw FFP.
Plasma also can be warmed in 7 minutes using a micro-
wave oven; however, only ovens specifically constructed
for this task can be used, as standard microwaves will
destroy the function of most coagulation factors.
Thawed plasma must probably be used within 4 to 6
hours after release. A macroaggregate filter must be used
to avoid infusing microcrystals of unthawed plasma.
Prophylactic indications
Current recommendations advise against the use of
plasma for volume expansion, as it has been show that
colloids are not superior to crystalloids [47], and plasma
transfusions are associated with a worse clinical outcome
[28]. Because a recent systematic review of 80 random-
ized, controlled trials did not find any significant benefit
of prophylactic use of plasma transfusions [48], a
prophylactic plasma transfusion strategy is not sup-
ported. However, most experts advocate prophylactic
plasma transfusion in case of surgery or invasive proce-
dures in patients with abnormal coagulation tests.
Therapeutic indications
Massive transfusions
Patients who are massively bleeding (transfused between
40–80 ml/kg of RBCs in a 24-hour period) have
dilutional coagulopathy as well as coagulation factor
consumption that might be corrected with plasma trans-
fusions. Most experts suggest not waiting for coagulation
tests before transfusing plasma units. The optimal RBC:
plasma:platelet ratio is still unknown, but early use of
plasma and platelets seems to be associated with improved
outcome [49]. The use of rapid thromboelastography test-
ing to guide plasma transfusion in massively bleeding
patients, while still uncommon, is increasing over time.
Thromboelastography-based algorithms reduce both
transfusion requirements and blood loss in cardiac sur-
gery, liver transplantation, and massive trauma.
Bleeding patients
In nonmassive bleeding patients, expert consensus is
that plasma should be considered only if the PT ratio or
aPTT ratio are > 1.5 [1,30] or if INR is >2 [40]. Norecommendations in this population currently include
thromboelastography thresholds for plasma transfusion.
Acute disseminated intravascular coagulation (DIC) in
conjunction with active bleeding
In bleeding patients with DIC, some physicians give
10–15 ml/kg of plasma, in association with the correc-
tion of the underlying cause. However, this strategy has
never been adequately evaluated.
Liver disease
In children undergoing liver transplantation, plasma
transfusions are associated with increased 1-year mortal-
ity [50]. Therefore, it seems reasonable to transfuse
plasma only in the setting of a severe bleeding with ab-
normal coagulation tests.
Surgical or invasive procedure
Plasma also is often used to try to prevent bleeding
before surgical procedures or invasive procedures in
patients with abnormal coagulation tests. It has been
shown that abnormal coagulations tests are not corre-
lated with an increased risk of bleeding [45]. However,
there are no data regarding this transfusion strategy.
Single clotting factor deficiencies
In patients with single clotting factor deficiency and ac-
tive bleeding, experts recommend that plasma should
only be transfused if specific concentrate is not obtain-
able. Usually, this only applies to factor V deficiency.
Reversal of warfarin effect
Warfarin causes a functional deficit of factors II, VII, IX,
and X, as well as proteins C and S. Plasma should only
be used for the reversal of warfarin if there is evidence
of severe bleeding or intracranial haemorrhage. If avail-
able, prothrombin complex is the first-choice treatment.
Hereditary angioedema (Quince oedema)
The purpose of treatment of acute episodes is to halt
progression of the oedema as quickly as possible. The
most efficient treatment is C1 inhibitor concentrate
from donor blood, which must be administered intraven-
ously. If C1-esterase inhibitor is not available, plasma
transfusions can be used to treat these patients.
Haemorrhagic disease of the newborn
In neonates, coagulation test have a wider normal range
than in adult and therefore are even less correlated to
the risk of bleeding. As for older children, there are no
data to recommend prophylactic plasma transfusions. In
case of significant bleeding, some experts recommend
giving plasma (15 ml/kg) and intravenous vitamin K.
Labarinas et al. Annals of Intensive Care 2013, 3:16 Page 6 of 7
http://www.annalsofintensivecare.com/content/3/1/16Current recommendations against the use of plasma
– Plasma should not be used as volume replacement,
because there is no advantage of colloids over
crystalloids for this indication [47].
– Plasma should not be used to correct abnormal INR
or PTT in nonbleeding patients who have no
planned surgery or invasive procedures, because
there is no correlation between coagulation tests and
risk of bleeding [45], but data show that plasma
transfusions increase the risk of unfavourable
outcome [27,28].
Future directions
There are many unresolved questions regarding plasma
transfusions. Apart from massively bleeding patients, it
is still unknown which patients really benefit from
plasma transfusions. Is it appropriate to give prophylac-
tic plasma transfusions to patients with abnormal
coagulation tests who will undergo surgery? Should we
transfuse plasma to patients who experience minor
bleeding? Randomized, controlled trials on plasma trans-
fusion strategies in these different clinical situations are
warranted.
Currently, it is unclear which coagulation test best re-
flects the risk of bleeding. Therefore, it is still unclear
what the appropriate plasma transfusion triggers should
be. Some experts suggest that thromboelastography tests
are superior to classical coagulation tests. However, no
studies have yet shown that a thromboelastography-
based goal-directed transfusion strategy improves mor-
tality in critically ill children.
Conclusions
Plasma transfusion is a common treatment for critical care
patients. Although it clearly benefits some patients, such
as those who are massively bleeding, epidemiological stud-
ies suggest that, in less dramatic situations, plasma trans-
fusions are associated with worse outcome, both in adults
and children. Therefore, the decision to proceed with
plasma transfusion must be based on individualized indi-
cations, while balancing the risks and benefits.
Unfortunately, no randomized, controlled trial has yet
addressed the appropriate plasma transfusion threshold.
Despite current expert recommendations based on ob-
servational data, most physicians prescribe plasma trans-
fusions according to their own believe and experiences.
This probably leads to many unnecessary transfusions
and therefore preventable adverse events.
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